Please assess the completion status of the following clinical trial:

Trial Title: Study of OTO-104 in Subjects With Unilateral Meniere's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject has a diagnosis of unilateral Meniere's disease by 1995 American Academy of Otolaryngology - Head and Neck Surgery (AAOHNS) criteria and reports active vertigo for the 2 months prior to the study lead-in period.~* Subject has experienced active vertigo during the lead-in period.~* Subject has documented asymmetric sensorineural hearing loss.~* Subject agrees to maintain their current treatments for Meniere's disease while on-study.~Exclusion Criteria includes, but is not limited to:~* Subject is pregnant or lactating.~* Subject has a history of immunodeficiency disease.~* Subject has a history of previous endolymphatic sac surgery.~* Subject has a history of previous use of intratympanic (IT) gentamicin in the affected ear.~* Subject has a history of tympanostomy tubes with evidence of perforation or lack of closure.~* Subject has experienced an adverse reaction to IT injection of steroids.~* Subject has used an investigational drug or device in the 3 months prior to screening.~* Subject has previously been randomized to a trial of OTO-104.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- OTO-104 (Type: EXPERIMENTAL): 12 mg dexamethasone
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).